Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 70Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Rectal Neoplasms 13Colonic Neoplasms 13Neoplasm Metastasis 12Esophageal Neoplasms 11Neoplasms 9Gallbladder Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Bile Duct Neoplasms 7Liver Neoplasms 6Adenocarcinoma Of Esophagus 5Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Gastrointestinal Neoplasms 3Esthesioneuroblastoma, Olfactory 3Esophageal Squamous Cell Carcinoma 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Pancreatic Intraductal Neoplasms 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Carcinoma, Renal Cell 2Biliary Tract Neoplasms 2Anus Neoplasms 2Adenomatous Polyposis Coli 2

Interventions

Liver Transplantation 1Erlotinib Hydrochloride 1Endoscopic Ultrasound-Guided Fine Needle Aspiration 1Cholangiopancreatography, Endoscopic Retrograde 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangitis, Sclerosing × Erlotinib Hydrochloride × Gastrointestinal × Clear all
NCT00955149 2014-01-10

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Mayo Clinic

Phase 1 Completed
6 enrolled
Gastrointestinal

Cholangitis, Sclerosing, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡